

This is a repository copy of The role of conformational flexibility in  $\beta$ 2-microglobulin amyloid fibril formation at neutral pH.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/83114/

Version: Accepted Version

## Article:

Hodkinson, JP, Radford, SE and Ashcroft, AE (2012) The role of conformational flexibility in  $\beta$ 2-microglobulin amyloid fibril formation at neutral pH. Rapid Communications in Mass Spectrometry, 26 (16). 1783 - 1792. ISSN 0951-4198

https://doi.org/10.1002/rcm.6282

#### Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

#### Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

## The role of conformational flexibility in β<sub>2</sub>-microglobulin amyloid fibril formation at neutral pH

John P. Hodkinson, Sheena E. Radford\*, Alison E. Ashcroft\*

Astbury Centre for Structural Molecular Biology, Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK

\* To whom correspondence should be addressed

Tel/fax: +44 113 343 7273

Email: <u>a.e.ashcroft@leeds.ac.uk</u> or <u>s.e.radford@leeds.ac.uk</u>

**Running Title:** Conformational flexibility in  $\beta_2$ m amyloid formation at pH 7

Keywords: β<sub>2</sub>-microglobulin, electrospray ionization, hydrogen/deuterium exchange, amyloid fibril

## Abstract

**RATIONALE:** Amyloid formation is implicated in a number of human diseases.  $\beta_2$ microglobulin ( $\beta_2$ m) is the precursor protein in dialysis-related amyloidosis and it has been shown that partial, or more complete, unfolding is key to amyloid fibril formation in this pathology. Here the relationship between conformational flexibility and  $\beta_2$ m amyloid formation at physiological pH has been investigated.

**METHODS:** HDX-ESI-MS was used to study the conformational dynamics of  $\beta_2$ m. Protein engineering, or the addition of Cu<sup>2+</sup> ions, sodium dodecyl sulphate, trifluoroethanol, heparin, or protein stabilisers were employed to perturb the conformational dynamics of  $\beta_2$ m. The fibril-forming propensities of the protein variants and the wild-type protein in the presence of additives which resulted in >5-fold increase in the EX1 rate of HDX were investigated further.

**RESULTS:** ESI-MS revealed that HDX occurs via a mixed EX1/EX2 mechanism under all conditions. Urea denaturation and tryptophan fluorescence indicated that EX1 exchange occurred from a globally unfolded state in wild-type  $\beta_2$ m. Although >30-fold increase in the HDX exchange rate was observed both for the protein variants and for the wild-type protein in the presence of specific additives, large increases in exchange rate did not necessarily result in extensive *de novo* fibril formation.

**CONCLUSION:** The conformational dynamics measured by the EX1 rate of HDX do not predict the ability of  $\beta_2$ m to form amyloid fibrils *de novo* at neutral pH. This suggests that the formation of amyloid fibrils from  $\beta_2$ m at neutral pH is dependent on the generation of one or more specific aggregation-competent species which facilitate self-assembly.

## Introduction

The ability to form amyloid fibrils, a generic property of possibly all polypeptide chains, is driven by main-chain/main-chain interactions, which are modulated by the sequence of amino acid side-chains.<sup>[1]</sup> In natively-structured proteins, aggregation-prone sequences are usually sequestered from solvent by the tertiary structure of the protein, with the result that self-assembly can only take place once unfolding from the native state occurs and exposes the aggregation-prone region.<sup>[2]</sup> This idea is known as the 'conformational change hypothesis' and is supported by the fact that amyloid fibril precursors can exhibit all types of secondary structure organisation, whereas amyloid fibrils exhibit a characteristic, common cross-beta structure.<sup>[3]</sup> Examples supporting the conformational change hypothesis in which a native protein undergoes significant re-organisation to form the amyloid fold include transthyretin,<sup>[4]</sup> lysozyme,<sup>[5]</sup> prion<sup>[6]</sup> and light chain amyloidosis.<sup>[7]</sup> Consistent with this, *in vitro* studies have shown that denaturation or destabilisation of the native state of globular proteins can increase amyloidogenicity.<sup>[1, 2, 4-9]</sup>

 $\beta_2$ -microglobulin ( $\beta_2$ m) is a 99-amino acid protein that exhibits a typical immunoglobulin fold comprising seven  $\beta$ -strands which form an anti-parallel  $\beta$ -sandwich structure stabilised by an inter-strand disulphide bridge between residues 25 and 80 (Figure 1).<sup>[10,11]</sup> The  $\beta_2$ m sequence contains five proline residues, of which four are in the *trans* conformation, and one, proline 32, is in the *cis* conformation in the natively-folded protein.<sup>[10]</sup>  $\beta_2$ m has an important physiological role as the light chain of the major histocompatibility complex class I (MHC-1) and its sequence has evolved to optimise its role as a chaperone during MHC-1 assembly.<sup>[12]</sup> This evolutionary pressure for function has resulted in a sequence with amyloid propensity when dissociated from the heavy chain of this complex.<sup>[9, 13, 14]</sup> Akin to other proteins which form amyloid fibrils commencing from a stably-folded native structure, conformational change is also necessary for amyloid formation from  $\beta_2 m$ .<sup>[15, 16]</sup> It has been shown that, at physiological temperature and pH, wild-type human  $\beta_2 m$  does not form amyloid fibrils spontaneously *in vitro*, even when incubated for long periods of time at high protein concentration.<sup>[17,18]</sup> This finding led to the investigation of alternative conditions under which  $\beta_2 m$  could be induced to form amyloid fibrils *in vitro* and the discovery that at acidic pH,  $\beta_2 m$  rapidly and extensively assembles into fibrils that possess all of the characteristic structural, tinctorial and ligand binding properties of amyloid.<sup>[19-21]</sup> Given that 60 % of the sequence of  $\beta_2 m$  is predicted to be highly amyloidogenic by various algorithms and by studies of isolated peptides,<sup>[9]</sup> it is not surprising that unfolding the protein with acidic pH results in rapid fibril formation.<sup>[20, 21]</sup> These observations support the view that conditions or mutations which increase the conformational flexibility of the protein will also enhance its amyloidogenic potential.<sup>[13, 22-25]</sup>

The conformational flexibility of wild-type human  $\beta_{2m}$  under native conditions has been investigated by hydrogen deuterium exchange (HDX) monitored by electrospray ionisation mass spectrometry (ESI-MS), capillary electrophoresis and NMR.<sup>[13, 22, 23, 25, 26]</sup> HDX-ESI-MS is particularly well suited to uncovering unfolded species within a native protein ensemble because exchange arising from uncorrelated conformational fluctuations (EX2) can be differentiated from exchange arising from transient, large-scale unfolding events (EX1) under appropriate conditions. From these studies, an unprotected conformer detected through EX1 exchange at pH 7 has been implicated in  $\beta_{2m}$  amyloid fibril formation under native conditions.<sup>[13, 22, 23, 25]</sup> However, the nature of this unprotected species remained unclear. Here we investigate the role of conformational dynamics of  $\beta_{2m}$  in the formation of amyloid fibrils under native-like conditions (pH 7, 37 °C). We show that hydrogen exchange from the native protein (N) under these conditions occurs by a mixed EX1/EX2 regime in which the native protein is in equilibrium with partially protected conformers, as well as the globally unfolded state (U). In addition, we use protein engineering, together with the addition of  $Cu^{2+}$  ions, trifluoroethanol (TFE), sodium dodecyl sulphate (SDS), low molecular weight (LMW) heparin or the protein stabilisers trimethyl amine oxide (TMAO), sarcosine and trehalose, to modulate the conformational dynamics of the wild-type protein visualised by the EX1 rate of exchange and then determine whether amyloid fibril formation is observed under the conditions selected. The results show that although the EX1 rate of exchange can be varied up to 35-fold by means of the techniques described, a substantial increase in the EX1 rate alone does not predict whether amyloid fibrils will be formed *de novo* within a set timescale.

## **Experimental**

#### Mutagenesis and protein purification

Wild-type human  $\beta_2 m$  and its variants were expressed and purified as described previously.<sup>[27]</sup> Murine  $\beta_2 m$  was expressed and purified as described previously.<sup>[28]</sup>

# $D \rightarrow H$ exchange of wild-type $\beta_2 m$ and variants in the presence of $Cu^{2+}/TFE/SDS$ or stabilisers monitored by ESI-MS

Fully deuterated protein<sup>[13]</sup> solution (lyophilised  $\beta_2$ m dissolved in 99.9 % D<sub>2</sub>O buffered to pH 8.0 using 5 mM TrisHCl and made up to a final protein concentration of 600  $\mu$ M) was diluted 25-fold into protonated 10 mM ammonium formate/ 10 mM ammonium acetate buffer containing the appropriate additive at pH 7.0 to initiate HDX. The solution was mixed using a vortex mixer and returned to a waterbath at the appropriate temperature. An aliquot (200  $\mu$ L) of the reaction mixture was removed from the Eppendorf vial at selected time-points, loaded onto a 5 mL HiTrap desalting column (GE Healthcare Life Sciences, Buckinghamshire, UK) and eluted rapidly with the same buffer (without additives). The eluate was transferred to the

NanoMate (Advion Biosciences Inc., Ithaca, NY, USA) autosampler and nanoESI interface of the mass spectrometer. The sample was ionised and desolvated by nanoESI (nitrogen nebulising gas pressure 0.4 psi, capillary voltage 1.8 kV), and analysed by use of an LCT Premier TOF mass spectrometer (Waters UK Ltd., Manchester, UK) with the following instrument settings: cone voltage: 70 V; ion guide: 70 V; aperture: 10 V; ion energy: 100 V.

## Analysis of the ESI-MS data

ESI-MS data were processed with the MassLynx 4.1 software supplied with the mass spectrometer (Waters UK Ltd., Manchester, UK). The data were smoothed twice with the Savitsky-Golay algorithm and centred by peak area. Each spectrum was fitted to two sets of Gaussian curves centred on the EX1 and EX2 base peaks with the software Igor Pro v5.4 (Wavemetrics Inc, Portland, OR, USA). The base peaks were linked to three additional peaks: base peak minus 28 Da, base peak plus 22 Da (Na<sup>+</sup> adduct) and base peak plus 38 Da (K<sup>+</sup> adduct). The peak positions of the adducts were determined in each spectrum by linking them to the base peak ( $\pm 0.2 \text{ m/z}$ ). The adduct peak width was fixed relative to the base peak ( $\pm 0.1 \text{ m/z}$ ) and the adduct peak height was fixed according to the ratio relative to the base peak observed in the initial and final spectra ( $\pm 10 \%$ ). The area and mass of each peak were determined at each time point during the HDX reaction by use of this method.

## Unseeded fibril growth at pH 7.0 in the presence of additives

Each protein solution (84  $\mu$ M) containing 0.02 % (*w/v*) sodium azide, 10  $\mu$ M thioflavin T (ThT), the required concentration of additive and 10 mM ammonium formate/ 10 mM ammonium acetate buffer was brought to pH 7.0 with hydrochloric acid and then passed through an Anotop 0.2  $\mu$ m syringe filter (Whatman UK Ltd., Kent, UK). A small volume of the solution (50  $\mu$ L/well) was pipetted into a 384-well plate with the required number of

replicates. The plates were sealed with clear plastic film. The fluorescence of ThT was excited (444 nm), and the emitted fluorescence measured at 480 nm at hourly time-intervals at 37 °C with a Fluostar Optima plate reader (BMG Labtech GmbH, Offenburg, Germany) with continuous shaking at 200 rpm.

## **Electron microscopy (EM)**

An aliquot of sample at the end of each fibril growth assay (14 days) was pipetted onto a sheet of parafilm. A freshly ionised formvar/carbon-coated EM grid was placed with the coated side onto the droplet and allowed to stand for 30 seconds. Remaining sample solution was removed with filter paper and 10  $\mu$ L of 4 % (*w*/*v*) uranyl acetate solution was pipetted onto the parafilm. The grid was again placed coated side down onto the droplet for 30 seconds. Excess uranyl acetate solution was removed with filter paper and the grid was air dried. Electron micrographs of the samples were taken with a JEOL 1200 electron microscope (Jeol Ltd., Tokyo, Japan) at suitable magnification depending on the sample being analysed.

## Determination of the unfolding rate of human wild-type $\beta_2 m$

100  $\mu$ L of 84  $\mu$ M protein in 10 mM ammonium formate/ 10 mM ammonium acetate buffered to pH 7 was mixed with the appropriate volume of 9 M urea dissolved in the same buffer mixture to yield the required final urea concentration at 37 °C. This mixture was immediately transferred into a pre-warmed cuvette. The cuvette contained a magnetic stirring bar which was used at 200 rpm during the analysis of the samples. The fluorescence of the protein was measured at 350 nm (using excitation at 280 nm) for 12 min or until the signal reached equilibrium in a QuantaMaster UV/VIS fluorescence spectrometer (Photon Technology International Inc., NJ, USA).

## Results

## $\beta_2$ m visits a globally unfolded conformation under physiological conditions

It has been shown previously that HDX of native wild-type human  $\beta_2$ m at pH 7, 37 °C occurs by a mixed EX1/EX2 mechanism.<sup>[13, 23, 25]</sup> To investigate the mechanism of HDX of  $\beta_2 m$ further, and specifically to determine whether exchange via the EX1 regime reflects global or sub-global unfolding events, the fully deuterated protein was diluted 25-fold into protonated buffer at pH 7, 37 °C and exchange was monitored by ESI-MS (see Experimental). Consistent with previous results,<sup>[13, 23]</sup> the spectra show that deuteron exchange (D $\rightarrow$ H) from the native, protected state occurs in part by local/uncorrelated motions (which result in a gradual decrease in mass of the fully protected species indicative of an EX2 mechanism of exchange (coloured red in Figure 2A)). In addition, HDX occurs concomitantly by correlated conformational fluctuations to a species that initially protects only 20 deuterons from exchange (characteristic of an EX1 mechanism of exchange (coloured blue in Figure 2A)). These residual 20 deuterons subsequently exchange via an apparent EX2 mechanism until exchange is complete (Figure 2A). This behaviour has been observed for other proteins<sup>[29, 30]</sup> and, in a two-state protein, may result from residual protection in the unfolded state, or competition between  $k_f$  (the refolding rate constant) and  $k_{int}$  (the rate constant of exchange from the unprotected state).

To determine the rate of HDX occurring by the EX1 mechanism, the spectra were integrated and software deconvolution was employed to determine the mass and population of the different species formed *versus* time, taking account of any ion adducts to each species (see Experimental). The results revealed that exchange to the unprotected state occurs with a rate constant of  $0.01\pm0.001$  min<sup>-1</sup> (Figure 2B). To illuminate whether the apparent EX2 exchange of the 20 protected residues results from residual structure in the unfolded state or competition between  $k_f$  and  $k_{int}$ , the pH dependence of the apparent EX2 exchange was investigated. An increase in the pH by one unit should increase  $k_{int}$  10-fold. If the phenomenon described results from rate competition, then as  $k_{int}$  is increased the extent of proton exchange by apparent EX2 kinetics should decrease. The data showed that as the pH is reduced from pH 7 to pH 5 the magnitude of the m/z shift of the post EX1 exchange ion (coloured blue in Figure 2A) increased by 7 Da. Similarly, as the pH is increased from pH 7 to pH 9 the magnitude of the apparent EX2 m/z shift of this peak reduced to zero. The results suggest, therefore, that the protein is visiting a globally unprotected conformation across the pH range 5-9, but it is only at pH 9 that the  $k_{int}$  is sufficiently rapid, relative to the refolding rate constant, to ensure complete exchange of all exposed residues upon visiting this globally unprotected state.

To determine whether the unprotected state of  $\beta_2 m$  visualised by EX1 exchange is globally unfolded, or represents a more structured yet unprotected state, the unfolding rate constant (k<sub>u</sub>) of  $\beta_2 m$  was measured by dilution of the native protein into high concentrations of urea and the rate of unfolding monitored by the fluorescence of tryptophan residues (Figure 3A). The data revealed that the protein unfolds by a single exponential function and that the logarithm of the rate constant of unfolding depends linearly on the concentration of denaturant (Figure 3B). Extrapolation of these data yields an unfolding rate constant in the absence of denaturant of  $0.01 \pm 0.001 \text{ min}^{-1}$ , a value identical to the rate of EX1 exchange measured by HDX-MS under these conditions (Figures 2B and 3B). The results indicate that exchange by EX1 kinetics results from global unfolding and that native  $\beta_2 m$  visits a globally unfolded, highly unprotected conformational state transiently under conditions in which the protein appears compactly folded.<sup>[11, 16, 31]</sup> The following analyses, therefore, focussed on investigating the EX1 exchange rate to explore the importance of kinetic stability and the probability of global unfolding for the self-aggregation of  $\beta_2 m$  at neutral pH. These data also pose the intriguing question of why evolution has allowed  $\beta_2 m$  to retain a high level of kinetic instability and to sample the unfolded state regularly, which would ordinarily pose a risk of aggregation.<sup>[32]</sup>

## Varying the frequency of visiting the unfolded state with solvent additives or protein engineering

To explore the possibility that global unfolding of native  $\beta_2$ m at pH 7.0 determines the ability of the protein to form amyloid fibrils at neutral pH, conditions were explored that enhance or reduce the probability of global unfolding, as determined by the rate of EXI HDX, and the effect of these alterations in protein dynamics on fibril formation was monitored in parallel. These conditions involved the use of  $\beta_2 m$  variants or incubating the wild-type protein in buffer at pH 7.0 in the presence of additives that alter the stability of the native state. In each case, the EX1 HDX rate was determined at pH 7.0 by ESI-MS. The variants selected for analysis were chosen from an array previously shown to display a wide variation in thermodynamic stability and amyloid potential: namely I7A, V37A, P32G, and  $\Delta$ N6 (Figure 1).<sup>[15,18,27,33,35]</sup> Specifically, the mutation I7A truncates a buried aliphatic side-chain and destabilises  $\beta_{2m}$  by 6 kJ mol<sup>-1</sup> ( $\Delta G_{UN}^{0} = -10.3$  kJ/mol compared with  $\Delta G_{UN}^{0} = -16.5$  kJ mol<sup>-1</sup> for wild-type  $\beta_2$ m at pH 7.0, 37 °C). This sequence alteration results in a protein able to form fibrils at pH 7.0 in vitro, albeit with low yield.<sup>[27,35]</sup> V37A destabilises  $\beta_2 m$  substantially  $(\Delta G^0_{UN} = -4.7 \text{ kJ mol}^{-1} \text{ at pH 7.0, 37 °C})$ , yet does not enable fibril formation at this pH.<sup>[18,27]</sup> P32G is mildly destabilised ( $\Delta G^0_{UN} = -11.4 \text{ kJ mol}^{-1}$  at pH 7.0, 37 °C) and enhances the ability of  $\beta_2 m$  to elongate fibril seeds, but this protein cannot nucleate fibril assembly at neutral pH.<sup>[15]</sup> The variant  $\Delta N6$  (a protein which lacks the N-terminal six amino acids) was included in the analysis as this protein is also mildly destabilised ( $\Delta G^0_{UN} = -12.0 \text{ kJ mol}^{-1}$  at pH 7.0, 37 °C) and, uniquely amongst the set of protein sequences studied, is able to nucleate fibril formation efficiently at neutral pH.<sup>[31,33,36]</sup> Finally, murine  $\beta_2 m$  was analysed because this protein, despite sharing 70 % sequence identity with human  $\beta_2 m$ ,<sup>[28,35]</sup> lacks the ability to form amyloid fibrils under acidic or neutral pH conditions.

In parallel with the mutagenesis studies, wild-type  $\beta_2 m$  was also incubated in the presence of a selection of additives which have been reported to endow a range of effects on aggregation propensity. Firstly, the divalent metal ions  $Cu^{2+}$ ,  $Zn^{2+}$  and  $Ni^{2+}$  were added.  $Cu^{2+}$  has been reported to facilitate amyloid fibril formation *de novo* from wild-type  $\beta_2 m$ , while the latter two ions have no effect, despite similar valence and size.<sup>[8,36,37]</sup> The co-solvent TFE (5-20 % (v/v)) was also employed because this solvent has been shown to enhance elongation of GAGstabilised  $\beta_2$ m seeds<sup>[38,39]</sup> and to promote the population of non-native conformers when added at a concentration of 5-20 % (v/v) at neutral pH.<sup>[38,39]</sup> SDS (0.5-2 mM) was included in this analysis as this anionic surfactant has been shown to promote partial unfolding of  $\beta_2$ m and to promote the elongation of fibril seeds at concentrations below its critical micellar concentration.<sup>[41]</sup> LMW heparin was included as a control additive, as this glycosaminoglycan has been shown to stabilise fibrils but to have little effect on the structure or stability of the  $\beta_{2m}$  monomer.<sup>[18]</sup> Additives which would be expected to stabilise native  $\beta_{2m}$  and reduce the probability of unfolding were also included. Accordingly, trehalose, sarcosine and trimethylamine-N-oxide (TMAO) were also used in these studies. These protein stabilisers were chosen for their known effect on the thermodynamic or kinetic stability of folded proteins and the consequent reduction in their aggregation propensity.<sup>[42,43]</sup> The choice of additives, solvents and sequence variants was designed to enable a systematic analysis of the HDX properties of  $\beta_2 m$  and, thereby, to determine if the dynamics of folded  $\beta_2 m$  correlate with the amyloidogenicity of the protein monomers.

Examples of the HDX kinetics of the different variants of  $\beta_2$ m and the wild-type protein in the presence of different additives are shown in Figure 4. Under all of the conditions explored, the proteins exchanged with mixed EX1/EX2 kinetics as shown for the wild-type protein in buffer alone (Figure 2). However, despite undergoing exchange by a similar mechanism, the rate of EX1 exchange varied widely throughout the different sequences and conditions used (Figure 5 and Table 1). For example, the addition of SDS (at concentrations >0.5 mM) or TFE (at concentrations >5 % (v/v)) results in a large (up to 35-fold) increase in the rate of HDX occurring by an EX1 mechanism. The addition of 2 mM SDS results in a >20-fold increase in the rate of EXI HDX kinetics, while the inclusion of 20 % ( $\nu/\nu$ ) TFE increases the EX1 rate of HDX by 35-fold. A large increase in EXI HDX kinetics was also apparent for the variants  $\Delta N6$  and P32G  $\beta_2 m$  for which the rates of HDX were too rapid to measure at 37 °C. Thus, for these variants, the temperature was reduced to 22 °C in order to obtain accurate measurement of their HDX rates (Table 1 and Figure 5). All of the variants tested exhibited increased conformational flexibility relative to wild-type  $\beta_2 m$  as judged by the rate of HDX, with murine  $\beta_2$ m showing a rate of EX1 HDX 5-fold greater that than of the human protein, while V37A and I7A showed EX1 HDX rates which were increased by 9- and 12-fold, respectively, relative to the wild-type human protein. Interestingly, the most kinetically unstable  $\beta_2 m$ variants, ( $\Delta$ N6 and P32G), are not the most thermodynamically unstable proteins (V37A and I7A  $\beta_2$ m), indicating a lack of correlation of the kinetic and thermodynamic stabilities of this protein. A modest increase (2-fold) in the EX1 rate of HDX was observed in the presence of a 2-fold molar excess of  $Cu^{2+}$ , while little, or no, increase (< 2-fold) occurred in the reactions containing a 2-fold molar excess of  $Ni^{2+}$  or  $Zn^{2+}$ . Finally, no change in the HDX properties of wild-type  $\beta_2 m$  were discernible in reactions incorporating LMW heparin, while up to 2-fold reduction in the rate of EXI HDX was evident upon addition of protein stabilisers, with the greatest effect observed with trehalose. Armed with this wide range of distinct effects on the

dynamic properties of  $\beta_2 m$ , we aimed to uncover whether kinetic instability is a generic basis for the amyloid propensity of this protein.

## The probability of global unfolding does not correlate with the probability of fibril formation

The data in Figure 5 indicate that by changing the solution conditions or sequence of  $\beta_2 m$ , the rate of EX1 HDX of the protein can be titrated over ~2 orders of magnitude. For example, a 70-fold decrease in the EX1 rate of exchange is observed when wild-type  $\beta_2$ m is incubated in the presence of 500 mM trehalose compared with the same protein incubated in the presence of 20 % ( $\nu/\nu$ ) TFE. The wide range of HDX rates observed in this analysis provides an opportunity to determine the role of conformational dynamics in determining the amyloid potential of  $\beta_2$ m monomers. To determine whether increasing the conformational flexibility of  $\beta_2$ m results in an enhanced ability to nucleate fibril formation at neutral pH, conditions in which the rate of EX1 HDX kinetics is increased >5-fold were selected for further analysis (indicated by the dashed line at 0.05 min<sup>-1</sup> in Figure 5). For these samples, the ability of the protein to form amyloid fibrils was monitored under identical solution conditions (37 °C, 10 mM ammonium acetate/ 10 mM ammonium formate buffer, pH 7.0, ± additives, with mild agitation) by use of thioflavin-T fluorescence (see Experimental). The fibril growth assay was performed for 14 days, at which point the presence or absence of fibrils was confirmed by negative stain transmission electron microscopy (EM). Of the 21 different solution conditions/variants studied using HDX, three conditions (wild-type  $\beta_2$ m in the presence of 20 % ( $\nu/\nu$ ) TFE, 1 mM or 2 mM SDS) and four variants ( $\Delta$ N6, P32G, I7A, V37A) resulted in an EX1 HDX rate that is increased >5-fold compared with that of the wild-type protein (Figure 5). Of these seven conditions/variants investigated, however, only two conditions (wild-type  $\beta_2$ m in the presence of 1 mM or 2 mM SDS), resulted in *de novo* fibril growth under the

conditions and timescales employed (Figure 6). Interestingly, wild-type  $\beta_2 m$  in 2 mM SDS resulted in a very rapid HDX rate (23-fold compared with wild-type  $\beta_2 m$  in buffer alone) (Figure 5) and these conditions resulted in rapid fibril formation (Figure 6Ai & ii). Addition of 1 mM SDS also resulted in *de novo* fibril formation in the 14 day timescale employed with a similar lag-time to that observed with 2 mM SDS (Figure 6A, i and iii), but only produced a 10-fold increase in the rate of EX1 HDX (Figure 5). The presence of 1 mM SDS resulted in a rate of EX1 HDX similar to that of V37A  $\beta_2 m$  (Figure 5), yet only the former conditions led to fibril growth under the timescale and conditions employed. None of the other conditions resulting in an enhanced rate (>5-fold) of EX1 HDX led to detectable fibril growth under the conditions employed (Figure 6 B-E). These analyses demonstrate that the probability of global unfolding measured by the rate of EX1 HDX kinetics does not correlate with the probability of amyloid fibril nucleation of  $\beta_2 m$ . Only for solutions containing 1-2 mM SDS does an increased rate of EX1 HDX correlate with *de novo* fibril formation. These conditions, therefore, result in unprotected species and solution conditions compatible with efficient fibril nucleation under the conditions explored<sup>[41]</sup>.

## Discussion

It has been well documented that native  $\beta_2$ m does not form amyloid fibrils in the absence of amyloid seeds *in vitro*, even when incubated at high concentration.<sup>[3,8]</sup> These earlier data confirm that conformational rearrangement of the natively-folded structure is necessary for fibril nucleation to occur,<sup>[3,15,31]</sup> but whether fibrillogenesis requires rearrangement to a native-like species or more highly unfolded species, or both, under different solution conditions remained unclear.<sup>[9,23,31,44]</sup> What is clear is that at neutral pH (pH 7, 37 °C) the conformation(s) required to nucleate fibril formation of  $\beta_2$ m are not populated sufficiently to allow assembly to proceed over an experimentally tractable timescale. Previously, it has been

shown by use of HDX-MS that  $\beta_2$ m bound to the MHC-1 heavy chain is conformationally stable and undergoes HDX by a pure EX2 mechanism, in marked contrast with the rapid dynamics that result in HDX occurring with an EX1 mechanism in monomeric  $\beta_2 m$ .<sup>[13]</sup> Although it is not unusual for proteins to cycle through many different conformational states under native conditions depending on their Boltzmann weight,<sup>[45]</sup> it is unusual for a thermodynamically stable protein to undergo exchange by an EX1 mechanism at pH 7 in the absence of denaturant, since the rapid refolding rate (k<sub>f</sub>) of most native proteins results in EX2 exchange kinetics at this pH.<sup>[46]</sup> Here we have re-examined the EX1 HDX kinetics of human  $\beta_2$ m by use of ESI-MS and, by comparison with the rate of global unfolding measured by denaturant jump experiments, revealed that the unprotected species identified by HDX-MS in buffer at pH 7.0 is the globally unfolded state. The data presented here also show that the frequency of visiting the unprotected (unfolded) state at pH 7.0 can be increased by incubation with additives such as SDS or TFE, or by alterations to the protein sequence. Interestingly, 5-20 % ( $\nu/\nu$ ) TFE and 0.5-10 mM SDS have been shown previously to enhance the rate of elongation of fibril seeds with  $\beta_2 m$  monomers,<sup>[38-41]</sup> while the different variants studied result in varied abilities to nucleate fibril growth.<sup>[15,27,28,31,35]</sup> Thus,  $\Delta N6$  is able to nucleate fibril formation efficiently at pH 7.0, I7A results in sparse fibril formation, and P32G, V37A and murine  $\beta_2m$  are not able to nucleate fibril growth at this pH.<sup>[15,27,28,31,35]</sup> Conditions that enhance the rate of EX1 HDX, therefore, do not enable the prediction of an ability to nucleate amyloid fibril formation. As well as reporting on the role of monomer dynamics in fibril growth, the results presented also highlight the importance of the solution conditions in determining fibril formation, with increased ionic strength and agitation often being required to drive fibril formation on a rapid (biochemically tractable) timescale even for a given pH and temperature.<sup>[47]</sup> As the studies presented here were performed at low ionic strength, so that identical conditions could be employed for both the HDX and fibril growth

assays, fibril nucleation was disfavoured. As a consequence, additives (e.g. TFE)<sup>[38,39]</sup> and variants  $(\Delta N6)^{[31,33]}$  known to enhance fibrillation at neutral pH failed to result in detectable fibril growth in 14 days in the volatile solvents employed here.

The highly dynamic nature of  $\beta_2 m$ , revealed here by HDX-MS, could influence fibril formation via two mechanisms. Firstly, enhanced conformational dynamics may result in the exposure of buried hydrophobic residues and/or the exposure of regions of the polypeptide chain (main-chain or side-chains) with unsatisfied hydrogen binding potential, that would enhance the probability of inter-molecular associations required to nucleate fibril growth. Alternatively, increased conformational flexibility could lead to the enhanced population of partially unfolded species under native conditions. Although an increased frequency of unfolding to the globally unfolded state gives proteins a greater opportunity to visit aggregation-competent conformations, the solution conditions must also favour the continued population of these alternative conformations in order for bimolecular associations to occur and the species generated to be populated for timescales commensurate with further fibril propagation. In the case of SDS and TFE it seems likely that although both additives cause frequent excursions to an unfolded state, SDS may endow thermodynamic stabilisation of an aggregation-competent conformation, whereas TFE does not offer this additional property. Thus, the action of SDS is two-fold: to provide  $\beta_2 m$  with an increased opportunity to sample alternative conformations and also to stabilise the resulting aggregation-competent intermediate and/or oligomeric states en route to fibril formation. This suggests that the population of specific, aggregation-competent intermediates is a pre-requisite to the formation of oligomeric species and consequently higher order fibrillar structures. Although frequent transitions to the unfolded state of  $\beta_2 m$  are likely to allow increased kinetic sampling of aggregation-competent conformations, we have shown here that this is not sufficient to enable

nucleation of  $\beta_2$ m fibril formation at neutral pH. It has been suggested that conformational flexibility is dampened by evolution to reduce the potential risk of aggregation as described above.<sup>[48]</sup> Here we show that monomeric  $\beta_2$ m displays unusually high kinetic instability for an immunoglobulin domain, presumably because the evolutionary pressure on its sequence has been to enable tight binding to the MHC heavy chain.

## Acknowledgements

JPH was funded by the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/SSH200511967). We thank Professor David Eisenberg (UCLA, USA) for the plasmid used to produce recombinant murine  $\beta_2$ m. We also thank Professor Andrew Miranker (Yale University, USA) for suggestions and advice regarding Cu<sup>2+</sup> induced  $\beta_2$ m fibrillogenesis. We also acknowledge with gratitude funding for the LCT Premier mass spectrometer from the Wellcome Trust (WT 075099/Z/04/Z). We thank members of the Ashcroft and Radford research groups for many helpful discussions during the course of this study.

## References

- [1] F. Chiti, C.M. Dobson. Protein misfolding, functional amyloid, and human disease. *Annu. Rev. Biochem.* **2006**, *75*, 333.
- [2] E. Monsellier, F. Chiti. Prevention of amyloid-like aggregation as a driving force of protein evolution. *EMBO Rep.* **2007**, *8*, 737.
- [3] T. Eichner, S.E. Radford. A diversity of assembly mechanisms of a generic amyloid fold. *Mol. Cell* **2011**, *43*, 8.
- [4] S.L. McCutchen, Z. Lai, G.J. Miroy, J.W. Kelly, W. Colon. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. *Biochemistry* **1995**, *34*, 13527.
- [5] G. Merlini, V. Bellotti. Lysozyme: A paradigmatic molecule for the investigation of protein structure, function and misfolding. *Clin. Chim. Acta*, **2005**, *357*, 168.
- [6] L. Kupfer, W. Hinrichs, M.H. Groschup, Prion protein misfolding. *Curr. Mol. Med.* **2009**, *9*, 826.
- [7] R. Raffen, L.J. Dieckman, M. Szpunar, C. Wunschl, P.R. Pokkuluri, P. Dave, P. Wilkins Stevens, X. Cai, M. Schiffer, F.J. Stevens. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. *Prot. Sci.* **1999**, *8*, 509.
- [8] C.M. Eakin, A.D. Miranker. From chance to frequent encounters: Origins of beta2microglobulin fibrillogenesis. *Biochim. Biophys. Acta - Proteins and Proteomics* **2005**, *1753*, 92.
- [9] G.W. Platt, S.E. Radford. Glimpses of the molecular mechanisms of beta2microglobulin fibril formation *in vitro*: Aggregation on a complex energy landscape. *FEBS Lett.* **2009**, *583*, 2623.
- [10] C.H. Trinh, D.P. Smith, A.P. Kalverda, S.E.V. Phillips, S.E. Radford. Crystal structure of monomeric human beta2-microglobulin reveals clues to its amyloidogenic properties. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 9771.
- [11] G. Verdone, A. Corazza, P. Viglino, F. Pettirossi, S. Giorgetti, P. Mangione, A. Andreola, M. Stoppini, V. Bellotti, G. Esposito. The solution structure of human

beta2-microglobulin reveals the prodromes of its amyloid transition. *Prot. Sci.* 2002, 11, 487.

- [12] M.A. Saper, P.J. Bjorkman, D.C. Wiley. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. *J. Mol. Biol.* **1991**, *219*, 277.
- [13] J.P. Hodkinson, T.R. Jahn, S.E. Radford, A.E. Ashcroft. HDX-ESI-MS reveals enhanced conformational dynamics of the amyloidogenic protein beta2-microglobulin upon release from the MHC-1. *J. Am. Soc. Mass Spectrom.* **2009**, *20*, 278.
- [14] G. Esposito, S. Ricagno, A. Corazza, E. Renella, D. Gumral, M.C. Mimmi, E. Betto, C.E. Pucillo, F. Fogolari, P. Viglino, S. Raimondi, S. Giorgetti, B. Bolognesi, G. Merlini, M. Stoppini, M. Bolognesi, V. Bellotti. The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. J. Mol. Biol. 2008, 9, 887.
- [15] T.R. Jahn, M.J. Parker, S.W. Homans, S.E. Radford. Amyloid formation under physiological conditions proceeds via a native-like folding intermediate. *Nat. Struct. Mol. Biol.* 2006, 13, 195.
- [16] D.P. Smith, K. Giles, R.H. Bateman, S.E. Radford, A.E. Ashcroft. Monitoring copopulated conformational states during protein folding events using electrospray ionization-ion mobility spectrometry-mass spectrometry. J. Am. Soc. Mass Spectrom. 2007, 18, 2180.
- [17] V.J. McParland, N.M. Kad, A.P. Kalverda, A. Brown, P. Kirwin-Jones, M.G. Hunter, M. Sunde, S.E. Radford. Partially unfolded states of beta2-microglobulin and amyloid formation *in vitro*. *Biochemistry* 2000, *39*, 8735.
- [18] S.L. Myers, S. Jones, T.R. Jahn, I.J. Morten, G.A. Tennent, E.W. Hewitt, S.E. Radford. A systematic study of the effect of physiological factors on beta2-microglobulin amyloid formation at neutral pH. *Biochemistry*. **2006**, *45*, 2311.
- [19] T.R. Jahn, G.A. Tennent, S.E. Radford. A common beta-sheet architecture underlies *in vitro* and *in vivo* beta2-microglobulin amyloid fibrils. *J. Biol. Chem.* 2008, 283, 17279.
- [20] W.S. Gosal, I.J. Morten, E.W. Hewitt, D.A. Smith, N.H. Thomson, S.E. Radford. Competing pathways determine fibril morphology in the self-assembly of beta2microglobulin into amyloid. *J. Mol. Biol.* **2005**, *351*, 850.
- [21] H. Naiki, N. Hashimoto, S. Suzuki, H. Kimura, K. Nakakuki, F. Gejyo, Establishment of a kinetic model of dialysis-related amyloid fibril extension *in vitro*. *Amyloid* **1997**, *4*, 223.
- [22] N.H. Heegaard, T.J. Jorgensen, L. Cheng, C. Schou, M.H. Nissen, O. Trapp. Interconverting conformations of variants of the human amyloidogenic protein beta2microglobulin quantitatively characterized by dynamic capillary electrophoresis and computer simulation. *Anal. Chem.* 2006, 78, 3667.
- [23] N.H. Heegaard, T.J. Jorgensen, N. Rozlosnik, D.B. Corlin, J.S. Pedersen, A.G. Tempesta, P. Roepstorff, R. Bauer, M.H. Nissen. Unfolding, aggregation, and seeded amyloid formation of lysine-58-cleaved beta2-microglobulin. *Biochemistry* 2005, 44, 4397.
- [24] H. Pal-Gabor, L. Gombos, A. Micsonai, E. Kovacs, E. Petrik, J. Kovacs, L. Graf, J. Fidy, H. Naiki, Y. Goto, K. Liliom, J. Kardos. Mechanism of lysophosphatidic acid-induced amyloid fibril formation of beta2-microglobulin *in vitro* under physiological conditions. *Biochemistry*, 2009, 48, 5689.
- [25] E. Rennella, A. Corazza, L. Codutti, V. Bellotti, M. Stoppini, P. Viglino, F. Fogolari, G. Esposito. Determining the energy landscape of proteins by a fast isotope exchange NMR approach. J. Am. Chem. Soc. 2012, 134, 4457.

- [26] E. Rennella, A. Corazza, F. Fogolari, P. Viglino, S. Giorgetti, M. Stoppini, V. Bellotti, G. Esposito. Equilibrium unfolding thermodynamics of beta2-microglobulin analyzed through native-state H/D exchange. *Biophys. J.*, 2009, 96, 169.
- [27] D.P. Smith, S. Jones, L.C. Serpell, M. Sunde, S.E. Radford. A systematic investigation into the effect of protein destabilisation on beta2-microglobulin amyloid formation. *J. Mol. Biol.* **2003**, *330*, 943.
- [28] M.I. Ivanova, M.R. Sawaya, M. Gingery, A. Attinger, D. Eisenberg. An amyloidforming segment of beta2-microglobulin suggests a molecular model for the fibril. *Proc. Natl. Acad. Sci. USA* 2004, 101, 10584.
- [29] H. Xiao, J.K. Hoerner, S.J. Eyles, A. Dobo, E. Voigtman, A.I. Mel'cuk, I.A. Kaltashov. Mapping protein energy landscapes with amide hydrogen exchange and mass spectrometry: I. A generalized model for a two-state protein and comparison with experiment. *Prot. Sci.* 2005, 14, 543.
- [30] L. Konermann, X. Tong, Y. Pan. Protein structure and dynamics studied by mass spectrometry: H/D exchange, hydroxyl radical labeling, and related approaches. J. Mass Spectrom. 2008, 43, 1021.
- [31] T. Eichner, S.E. Radford. A generic mechanism of beta2-microglobulin amyloid assembly at neutral pH involving a specific proline switch. J. Mol. Biol. 2009, 386, 1312.
- [32] F. Chiti, N. Taddei, F. Baroni, C. Capanni, M. Stefani, G. Ramponi, C.M. Dobson. Kinetic partitioning of protein folding and aggregation. *Nat. Struct. Biol.* **2002**, *9*, 137.
- [33] G. Esposito, R. Michelutti, G. Verdone, P. Viglino, H. Hernandez, C.V. Robinson, A. Amoresano, F. Dal Piaz, M. Monti, P. Pucci, P. Mangione, M. Stoppini, G. Merlini, G. Ferri, V. Bellotti. Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein aggregation and fibril formation. *Prot. Sci.* 2000, *9*, 831.
- [34] T. Eichner, A.P. Kalverda, G.S. Thompson, S.W. Homans, S.E. Radford. Conformational conversion during amyloid formation at atomic resolution. *Mol. Cell* **2011**, *41*, 161.
- [35] S. Jones, D.P. Smith, S.E. Radford. Role of the N- and C-terminal strands of beta2microglobulin in amyloid formation at neutral pH. *J. Mol. Biol.* **2003**, *330*, 935.
- [36] M.F. Calabrese, A.D. Miranker. Formation of a stable oligomer of beta2microglobulin requires only transient encounter with Cu(II). J. Mol. Biol. 2007, 367, 1.
- [37] C.M. Eakin, J.D. Knight, C.J. Morgan, M.A. Gelfand, A.D. Miranker. Formation of a copper specific binding site in non-native states of beta2-microglobulin. *Biochemistry* 2002, 41, 10646.
- [38] S. Yamamoto, I. Yamaguchi, K. Hasegawa, S. Tsutsumi, Y. Goto, F. Gejyo, H. Naiki. Glycosaminoglycans enhance the trifluoroethanol-induced extension of beta2microglobulin-related amyloid fibrils at a neutral pH. J. Am. Soc. Nephrol. 2004, 15, 126.
- [39] E. Rennella, A. Corazza, S. Giorgetti, F. Fogolari, P. Viglino, R. Porcari, L. Verga, M. Stoppini, V. Bellotti, G. Esposito. Folding and fibrillogenesis: Clues from beta2-microglobulin. J. Mol. Biol. 2010, 401, 286.
- [40] C. Santambrogio, S. Ricagno, F. Sobott, M. Colombo, M. Bolognesi, R. Grandori. Characterization of beta2-microglobulin conformational intermediates associated to different fibrillation conditions. *J. Mass Spectrom.* **2011**, 46, 734.
- [41] S. Yamamoto, K. Hasegawa, I. Yamaguchi, S. Tsutsumi, J. Kardos, Y. Goto, F. Gejyo, H. Naiki. Low concentrations of sodium dodecyl sulfate induce the extension

of beta2-microglobulin-related amyloid fibrils at a neutral pH. *Biochemistry* **2004**, *43*, 11075.

- [42] D.A. Beck, B.J. Bennion, D.O. Alonso, V. Daggett. Simulations of macromolecules in protective and denaturing osmolytes: Properties of mixed solvent systems and their effects on water and protein structure and dynamics. *Meth. Enzymol.* 2007, 428, 373.
- [43] Y. Zhang, P.S. Cremer. Chemistry of Hofmeister anions and osmolytes. Ann. Rev. Phys. Chem. 2010, 61, 63.
- [44] A. Corazza, E. Rennella, P. Schanda, M.C. Mimmi, T. Cutuil, S. Raimondi, S. Giorgetti, F. Fogolari, P. Viglino, L. Frydman, M. Gal, V. Bellotti, B. Brutscher, G. Esposito. Native-unlike long-lived intermediates along the folding pathway of the amyloidogenic protein beta2-microglobulin revealed by real-time two-dimensional NMR. J. Biol. Chem. 2010, 285, 5827.
- [45] D.M. Ferraro, N.D. Lazo, A.D. Robertson. EX1 hydrogen exchange and protein folding. *Biochemistry* **2004**, *43*, 587.
- [46] D.D. Weis, T.E. Wales, J.R. Engen, M. Hotchko, L.F. Ten Eyck. Identification and characterization of EX1 kinetics in H/D exchange mass spectrometry by peak width analysis. J. Am. Soc. Mass Spectrom. 2006, 17, 1498.
- [47] Y. Goto, H. Yagi, K. Yamaguchi, E. Chatani, T. Ban. Structure, formation and propagation of amyloid fibrils. *Curr. Pharm. Des.* **2008**, *14*, 3205.
- [48] S. Raimondi, N. Barbarini, P. Mangione, G. Esposito, S. Ricagno, M. Bolognesi, I. Zorzoli, L. Marchese, C. Soria, R. Bellazzi, M. Monti, M. Stoppini, M. Stefanelli, P. Magni, V. Bellotti. The two tryptophans of beta2-microglobulin have distinct roles in function and folding and might represent two independent responses to evolutionary pressure. *BMC Evolutionary Biology* 2011, 11, 159.

## Table 1. EX1 rate of HDX-ESI-MS

Rate of EX1 HDX of wild-type human  $\beta_2$ m, its variants, and murine  $\beta_2$ m at pH 7.0 in the presence of a range of additives. All reactions were measured at 37 °C, except those marked with \* which were carried out at 22 °C.

Additive/ β <sub>2</sub> m variant	EX1 HDX rate (min <sup>-1</sup> )
Trehalose (500 mM)	$0.0047 \pm 0.00051$
Sarcosine (250 mM)	$0.0081 \pm 0.00072$
TMAO (250 mM)	$0.0078 \pm 0.00086$
LMW heparin (168 µM)	$0.0092 \pm 0.00096$
20 % (v/v) TFE	$0.347 \pm 0.035$
10 % (v/v) TFE	$0.046 \pm 0.006$
5 % ( <i>v/v</i> ) TFE	$0.02 \pm 0.0031$
2.0 mM SDS*	$0.227 \pm 0.016$
1.0 mM SDS	$0.099 \pm 0.0039$
0.75 mM SDS	$0.035 \pm 0.0019$
0.5 mM SDS	$0.0195 \pm 0.0012$
0.25 mM SDS	$0.0096 \pm 0.0011$
$\beta_2 m 1:2 Z n^{2+}$	$0.017 \pm 0.0018$
$\beta_2 m 1:2 Ni^{2+}$	$0.009 \pm 0.00075$
$\beta_2 m \ 1.2 \ Cu^{2+}$	$0.021 \pm 0.0027$
$\beta_2 m 1:1 Cu^{2+}$	$0.017 \pm 0.0016$
$\Delta N6 \beta_2 m^*$	$0.12 \pm 0.03$
P32G $\beta_2 m^*$	$0.026 \pm 0.002$
$I7A \beta_2 m$	$0.12 \pm 0.03$
$V37A\beta_2m$	$0.088 \pm 0.03$
Murine $\beta_2 m$	$0.05 \pm 0.02$
Human $\beta_2$ m (wild type)	$0.01 \pm 0.001$

## **Figure legends**

## Figure 1. Solution structure of β<sub>2</sub>m

The solution structure (PDB accession code 1JNJ)<sup>[29]</sup> of wild-type human  $\beta_2m$ . The residues/regions mutated in the four variants in these studies are highlighted:  $\Delta N6$  (green), I7A (dark blue), P32G (cyan) and V37A (pink). The position of the FG loop that differs markedly in sequence between human and murine  $\beta_2m$  is shown in black. The  $\beta$ -strands are annotated A-G and the disulphide bond is shown as an orange stick linking strands B and F.

## Figure 2. HDX-ESI-MS of wild-type β<sub>2</sub>m

A. D $\rightarrow$ H exchange of wild-type  $\beta_2$ m (pH 7.0, 37 °C). Protein molecules which have undergone exchange *via* an EX2 mechanism only are shown in red, those which have undergone exchange *via* both an EX2 and EX1 mechanism are shown in blue.

B. Plot showing the intensity of the EX1 peak relative to the total protein signal over time. The data are fitted to a single exponential (red line).

## Figure 3. Determination of wild-type β<sub>2</sub>m unfolding rate

A. Plot showing the unfolding of wild-type human  $\beta_2$ m measured using tryptophan fluorescence (pH 7.0, 37 °C) at increasing urea concentration (4.95-7.65 M urea in 0.45 M increments). The data are shown in grey and a single exponential fit to the data is shown as a black line.

B. Plot of the natural logarithm of the unfolding rate constant of wild-type human  $\beta_2$ m (pH 7.0, 37 °C) *versus* the urea concentration (M). The data are shown in grey and the linear fit to the data in black. The error on each point (2 standard deviations of the mean) is smaller than the data marker.

Figure 4. HDX-ESI-MS of wild-type  $\beta_2 m$  in presence of Cu<sup>2+</sup>, TFE or SDS and also of  $\Delta N6 \beta_2 m$ .

D $\rightarrow$ H exchange of wild-type human  $\beta_2$ m (pH 7.0, 37 °C) in the presence of (A) a 2-fold molar excess of Cu<sup>2+</sup> ions; (B) 10 % ( $\nu/\nu$ ) TFE; and (C) 1 mM SDS. (D) D $\rightarrow$ H exchange of  $\Delta$ N6  $\beta_2$ m (pH 7.0, 22 °C). In each case the left-hand image shows the mass profile of the ESI-MS spectrum. Protein molecules which have undergone exchange *via* an EX2 mechanism only are shown in red, while peaks that arise from molecules which have undergone exchange *via* both EX2 and EX1 mechanisms are shown in blue. Peaks in (A) and (D) at higher mass (grey) result from potassium and sodium adducts. The right-hand column shows plots of EX1 peak intensity relative to the total protein signal over time. The data are fitted to a single exponential (red line) in each case.

## Figure 5. EX1 rate of HDX-ESI-MS

The EX1 rate of HDX of wild-type human  $\beta_2 m$ , its variants and murine  $\beta_2 m$  in the presence of a range of different solution conditions. All reactions were measured at pH 7.0, 37 °C, except for those marked with \* which were carried out at 22 °C. The error bars depict two standard deviations of the mean. The dashed line denotes the threshold of a rate of HDX  $\geq$  5-times that of wild-type human  $\beta_2 m$ .

## Figure 6. Fibril growth assay

Fibril growth assays at pH 7.0, 37 °C with shaking at 200 rpm monitored by thioflavin-T fluorescence. A (i) wild-type  $\beta_2$ m in the presence of 2 mM SDS (blue) or 1 mM SDS (red). Negative stain EM images of the fibrils resulting from incubation with (ii) 2 mM SDS and (iii) 1 mM SDS for 14 days are shown. B (i) wild-type human  $\beta_2$ m in the presence of 20 % ( $\nu/\nu$ ) TFE; (ii) the reaction end-point (14 days) observed by EM is shown. C (i)  $\Delta$ N6  $\beta_2$ m; (ii)

the reaction end-point (14 days) observed by EM is shown. D (i) I7A  $\beta_2$ m; (ii) the reaction end-point (14 days) observed by EM is shown. E (i) I7A  $\beta_2$ m; (ii) the reaction end-point (14 days) observed by EM is shown. Scale bars are shown in red and indicate 500 nm.

## Figures

Figure 1.






Figure 2.







## Figure 4.




Figure 5.




Figure 6.

